Results 71 to 80 of about 149,997 (261)

Pharmacological chromatin remodeling enhances response to estrogen therapy in ER+ breast cancer

Molecular Oncology, EarlyView.
Estrogen therapy elicits clinical benefit in ~ 30% of patients with endocrine‐resistant estrogen receptor (ER)‐positive breast cancer. Based on findings that ER transcriptional activation underlies response to estrogen therapy, we tested the effects of epigenetic dysregulation via pharmacological inhibition of histone deacetylases (HDACi).
Anneka L. Johnson Thomas, Barbara Karakyriakou, Patricia C. Muskus, Alyssa M. Roberts, Justin Rendleman, Alexa Warren, Hanxu Lu, Kimberly A. Birmingham, Malone K. Friedman, Abigail E. Goen, Huijuan Yang, Owen M. Wilkins, Fred W. Kolling, Eugene Demidenko, Julie M. Jorns, Brock C. Christensen, Todd W. Miller   +16 more
wiley   +1 more source

Cancer cell‐intrinsic type 1 interferon: production, signaling, and outcomes within sex‐biased, female malignancies

Molecular Oncology, EarlyView.
The cell‐autonomous roles of interferon type 1 vary based on duration and intensity. While acute, robust signaling results in cancer cell cytotoxic effects, sustained, low‐level signaling is associated with tumor‐promoting effects. This review summarizes current research of IFN‐1 in cancer and within the clinical setting, with an emphasis on female ...
Ashlyn Conant, Nora Badiner, Sharon Asariah, Kiera McGivney, Vishwa Shah, Tise Suzuki, Yevgeniya J. Ioffe, Juli J. Unternaehrer   +7 more
wiley   +1 more source

Adjuvant radiotherapy for DCIS

The Lancet, 2000
Jeremy Millar, Alan Rodger
  +6 more sources

Predictive and Prognostic Factors in Ovarian and Uterine Carcinosarcomas

Balkan Medical Journal, 2016
Background: Prognostic factors and the standard treatment approach for gynaecological carcinosarcomas have not yet been clearly defined. Although carcinosarcomas are more aggressive than pure epithelial tumours, they are treated similarly.
İrfan Cicin, Tahsin Özatlı, Esma Türkmen, Türkan Özturk, Melike Özçelik, Devrim Çabuk, Ayşe Gökdurnalı, Özlem Balvan, Yaşar Yıldız, Metin Şeker, Nuriye Özdemir, Burcu Yapar, Özgür Tanrıverdi, Yusuf Günaydin, Serkan Menekşe, Berna Öksüzoğlu, Asude Aksoy, Bülent Erdoğan, M. Bekir Hacıoglu, Erkan Arpaci, Alper Sevinç, Mehmet Atilla Uysal, Sinem İliaz   +22 more
doaj   +1 more source

Long‐Term Follow‐Up of Chemotherapy‐Associated Biological Aging in Women With Early Breast Cancer

Aging and Cancer, EarlyView.
Women threated with adjuvant chemotherapy for early breast cancer have sustained long‐term increase in p16INK4a,, a robust marker of cell senescence, suggesting a chemotherapy‐associated age acceleration. p16INK4a as well as other biomarkers may identify patients at greatest risk for senescence‐related diseases of aging.
Hyman B. Muss, Alexis C. Wardell, Allison M. Deal, Kirsten A. Nyrop, Allison Ross, Yara G. Abdou, Jeffrey D. Aldrich, Lisa A. Cary, E. Claire Dees, Katherine E. Reeder‐Hayes, Emily M. Ray, Natalia Mitin, Denis Tsygankov   +12 more
wiley   +1 more source

Adjuvant radiotherapy and chemotherapy in breast cancer

Journal of British Surgery, 1986
Abstract Three hundred and twenty-two women with involvement of axillary lymph nodes following surgery for operable breast cancer were randomized to receive either postoperative radiotherapy, chemotherapy (CMF) or radiotherapy followed by chemotherapy.
C S, McArdle, D, Crawford, E H, Dykes, K C, Calman, D, Hole, A R, Russell, D C, Smith   +6 more
openaire   +2 more sources

Risk Prediction Models for Recurrence After Curative Treatment of Early‐Stage or Locally Advanced Lung Cancer: A Systematic Review

Aging and Cancer, EarlyView.
This systematic review synthesizes prognostic models for survival and recurrence in resected non‐small cell lung cancer. While many models demonstrate moderate to good discrimination, few are externally validated and reporting quality is variable, limiting clinical applicability and highlighting the need for robust, transparent model development ...
Evangeline Samuel, S. Tissera, E. Paul, J. Zalcberg, R. G. Stirling   +4 more
wiley   +1 more source

Postoperative Radiotherapy after Radical Prostatectomy: Indications and Open Questions

Prostate Cancer, 2012
Biochemical relapse after radical prostatectomy occurs in approximately 15–40% of patients within 5 years. Postoperative radiotherapy is the only curative treatment for these patients. After radical prostatectomy, two different strategies can be offered,
Pirus Ghadjar, Daniel Zwahlen, Daniel M. Aebersold, F. Zimmermann   +3 more
doaj   +1 more source

Five‐Year Outcomes of Laparoscopic Sphincter‐Preserving Surgery for Rectal Cancer: A Prospective Study in Elderly Vietnamese Patients

Aging and Cancer, EarlyView.
This prospective study demonstrates that laparoscopic sphincter‐preserving surgery is feasible for elderly patients. While overall survival reaches 70% at 5 years, advanced T‐stage and the omission of neoadjuvant therapy significantly drive recurrence, highlighting the need for personalized geriatric protocols despite logistical challenges.
Huu Duc Ho, Quang Le, Ngoc Thach Tran, Van Viet Ung, Loc Vu   +4 more
wiley   +1 more source

Distribution of oral carcinoma case requiring radiotherapy in the Oral and Maxillofacial Surgery Clinics

Padjadjaran Journal of Dentistry, 2015
Introduction: Carcinoma is a highly malignant tumour of epithelium that occurred in the oral cavity. One of the most common therapies given is radiotherapy, with healing, adjuvant, and palliative intentions.
Dinda Tegar Jelita, Lucky Riawan, Herman Hambali   +2 more
doaj   +1 more source